Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette subfamily G member 2

다국어 초록 (Multilingual Abstract)

Growth hormone receptor (GHR) plays a vital role in breast cancer chemoresistance and metastasis but the mechanism is not fully understood. We determined if GHR could be a potential therapeutic target for estrogen receptor negative (ER−ve) breast cancer, which are highly chemoresistant and metastatic. GHR was stably knocked down in ER-ve breast cancer cells and its effect on cell proliferation, metastatic behavior, and chemosensitivity to docetaxel (DT) was assessed. Microarray analysis was performed to identify potential GHR downstream targets involved in chemoresistance. GHR and ATP-binding cassette sub-family G member 2 (ABCG2) overexpression and knockdown studies were performed to investigate the mechanism of GHR-induced chemoresistance. Patient-derived xenografts was used to study the effect of GHR and ABCG2. Immunohistochemical data was used to determine the correlation between GHR, pAKT, pmTOR, and ABCG2 expressions. GHR silencing drastically reduced the chemoresistant and metastatic behavior of ER-ve breast cancer cells and also inhibited AKT/mTOR pathway. In contrast, activation, or overexpression of GHR increased chemoresistance and metastasis by increasing the expression and promoter activity, of ABCG2. Inhibition of JAK2/STAT5 signaling repressed GHR-induced ABCG2 promoter activity and expression. Further, ABCG2 knockdown significantly increased the chemosensitivity. Finally, patient-derived xenograft studies revealed the role of GHR in chemoresistance. Overall, these findings demonstrate that targeting GHR could be a novel therapeutic approach to overcome chemoresistance and associated metastasis in aggressive ER-ve breast cancers.

참고문헌 (Reference)

1 Dean, M., "Tumour stem cells and drug resistance" 5 : 275-284, 2005

2 Dent, R., "Triple-negative breast cancer : clinical features and patterns of recurrence" 13 : 4429-4434, 2007

3 Carey, L. A., "The triple negative paradox : primary tumor chemosensitivity of breast cancer subtypes" 13 : 2329-2334, 2007

4 Swanson, S. M., "The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis" 23 : 977-982, 2002

5 Divisova, J., "The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth" 98 : 315-327, 2006

6 Brooks, A. J., "The growth hormone receptor : mechanism of activation and clinical implications" 6 : 515-525, 2010

7 Hollier, B. G., "The epithelial-to-mesenchymal transition and cancer stem cells : a coalition against cancer therapies" 14 : 29-43, 2009

8 Kaulsay, K. K., "The effects of autocrine human growth hormone(hGH)on human mammary carcinoma cell behavior are mediated via the hGH receptor" 142 : 767-777, 2001

9 Perry, J. K., "The contribution of growth hormone to mammary neoplasia" 13 : 131-145, 2008

10 Cortes, J., "Targeting the microtubules in breast cancer beyond taxanes : the epothilones" 12 : 271-280, 2007

11 Yang, J., "Sustained growth in primary culture of normal mammary epithelial cells embedded in collagen gels" 77 : 2088-2092, 1980

12 Tang, J. Z., "STAT3alpha is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone" 151 : 4133-4145, 2010

13 Mao, Q., "Role of the breast cancer resistance protein(BCRP/ABCG2)in drug transport-an update" 17 : 65-82, 2015

14 Mao, Q., "Role of the breast cancer resistance protein(ABCG2)in drug transport" 7 : E118-E133, 2005

15 Subramani, R., "Role of growth hormone in breast cancer" 158 : 1543-1555, 2017

16 Wu, A. M., "Role of STAT5 and epigenetics in lactation-associated upregulation of multidrug transporter ABCG2 in the mammary gland" 307 : E596-E610, 2014

17 Sorlie, T., "Repeated observation of breast tumor subtypes in independent gene expression data sets" 100 : 8418-8423, 2003

18 Ikeno, Y., "Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice" 64 : 522-529, 2009

19 Yang, J., "Primary culture of human mammary epithelial cells embedded in collagen gels" 65 : 337-343, 1980

20 Mosly, D., "Predictive markers of endocrine response in breast cancer" 8 : 1-7, 2018

21 Mukhina, S., "Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone" 101 : 15166-15171, 2004

22 Arumugam, A., "Parity and short-term estradiol treatment utilizes similar cellular mechanisms to confer protection against breast cancer" 34 : 491-505, 2014

23 Paridaens, R., "Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer : a European Organization for Research and Treatment of Cancer Randomized Study with cross-over" 18 : 724-733, 2000

24 Rhodes, D. R., "ONCOMINE : a cancer microarray database and integrated data-mining platform" 6 : 1-6, 2004

25 Arumugam, A., "Neem leaf extract inhibits mammary carcinogenesis by altering cell proliferation, apoptosis, and angiogenesis" 15 : 26-34, 2014

26 Han, B., "Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2" 4 : 31-42, 2004

27 Stacy, A. E., "Molecular pharmacology of ABCG2 and its role in chemoresistance" 84 : 655-669, 2013

28 Rivera, E., "Management of metastatic breast cancer : monotherapy options for patients resistant to anthracyclines and taxanes" 33 : 176-185, 2010

29 Walia, V., "Loss of breast epithelial marker hCLCA2 promotes epithelial-tomesenchymal transition and indicates higher risk of metastasis" 31 : 2237-2246, 2012

30 Beckwith, H., "Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer : implications for targeted therapy" 20 : 1214-1221, 2014

31 Wu, A. M., "Induction of multidrug resistance transporter ABCG2by prolactin in human breast cancer cells" 83 : 377-388, 2013

32 Ansieau, S., "Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence" 14 : 79-89, 2008

33 Murphy, C. G., "Holding back the sea : the role for maintenance chemotherapy in metastatic breast cancer" 122 : 177-179, 2010

34 Gebre-Medhin, M., "Growth hormone receptor is expressed in human breast cancer" 158 : 1217-1222, 2001

35 Guevara-Aguirre, J., "Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans" 3 : 70ra13-, 2011

36 Minoia, M., "Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression" 97 : E907-E916, 2012

37 Felice, D. L., "Growth hormone potentiates 17beta-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling" 154 : 3219-3227, 2013

38 Zatelli, M. C., "Growth hormone excess promotes breast cancer chemoresistance" 94 : 3931-3938, 2009

39 Sorlie, T., "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications" 98 : 10869-10874, 2001

40 O’Shaughnessy, J., "Extending survival with chemotherapy in metastatic breast cancer" 10 (10): 20–29-, 2005

41 Kopchick, J. J., "Evaluation of growth hormone(GH)action in mice : discovery of GH receptor antagonists and clinical indications" 386 : 34-45, 2014

42 Hess, K. R., "Estrogen receptors and distinct patterns of breast cancer relapse" 78 : 105-118, 2003

43 Berry, D. A., "Effect of screening and adjuvant therapy on mortality from breast cancer" 353 : 1784-1792, 2005

44 Shin, S., "ERK2 but not ERK1induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events" 38 : 114-127, 2010

45 Yu, F., "Breast cancer prognosis signature: linking risk stratification to disease subtypes" 2018

46 Zekri, A., "Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis" 377 : 84-92, 2013